Jordi Bruix
Grupo de investigación
- Oncología hepática (BCLC) Emeritus researcher
Publicaciones destacadas
-
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Autores: Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J .Referencia: Lancet Oncology 2018. -
Hepatocellular carcinoma
Autores: Forner A; Reig M; Bruix J.Referencia: Lancet 2018. -
Complete response under sorafenib in patients with hepatocellular carcinoma. Relationship with dermatologic adverse events.
Autores: Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla A, Sangro B, Rodriguez de Lope C, Sala M, Gonzalez C, Huertas C, Minguez B, Ayuso C, Bruix J, Reig M .Referencia: Hepatology 2018. -
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Autores: Bruix, Jordi; Qin, Shukui; Merle, Philippe; Granito, Alessandro; Huang, Yi-Hsiang; Bodoky, Gyrogy; Pracht, Marc; Yokosuka, Osamu; Rosmorduc, Olivier; Breder, Valeriy; Gerolami, Rene; Masi, Gianluca; Ross, Paul J.; Song, Tianqiang; Bronowicki, Jean-Pierre; Ollivier-Hourmand, Isabelle; Kudo, Masatoshi; Cheng, Ann-Lii; Llovet, Josep M.; Finn, Richard S.; LeBerre, Marie-Aude; Baumhauer, Annette; Meinhardt, Gerold; Han, Guohong;Resorce Investigators.Referencia: Lancet 2017. -
Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution
Autores: Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J .Referencia: Journal Of Hepatology 2016. -
Liver transplantation for 'very early' intrahepatic cholangiocarcinoma. international retrospective study supporting a prospective assessment
Autores: Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCA International Consortium.Referencia: Hepatology 2016. -
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Autores: Bruix J, Reig M, Sherman M .Referencia: Gastroenterology 2016. -
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Autores: Bruix, Jordi; Takayama, Tadatoshi; Mazzaferro, Vincenzo; Chau, Gar-Yang; Yang, Jiamei; Kudo, Masatoshi; Cai, Jianqiang; Poon, Ronnie T.; Han, Kwang-Hyub; Tak, Won Young; Lee, Han Chu; Song, Tianqiang; Roayaie, Sasan; Bolondi, Luigi; Lee, Kwan Sik; Makuuchi, Masatoshi; Souza, Fabricio; Le Berre, Marie-Aude; Meinhardt, Gerold; Llovet, Josep M.;STORM Investigators.Referencia: Lancet Oncology 2015. -
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Autores: Reig, Maria; Torres, Ferran; Rodriguez-Lope, Carlos; Forner, Alejandro; Llarch, Neus; Rimola, Jordi; Darnell, Anna; Rios, Jose; Ayuso, Carmen; Bruix, Jordi.Referencia: Journal Of Hepatology 2014. -
Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design
Autores: Reig, Maria; Rimola, Jordi; Torres, Ferran; Darnell, Anna; Lope, Carlos Rodriguez-; Forner, Alejandro; Llarch, Neus; Rios, Jose; Ayuso, Carmen; Bruix, Jordi.Referencia: Hepatology 2013.
Proyectos destacados
-
A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).
Investigador/a principal: Jordi Bruix TudoFinanciador: AdaptimmuneCódigo: ADP-0033-001Duración: 01/01/2018 - 31/12/2033 -
Role and therapeutic potential of CPEB proteins in the transition from cirrhosis to hepatocellular carcinoma.
Investigador/a principal: Jordi Bruix TudoCódigo: 16-0026_BRUIXDuración: 01/02/2016 - 31/12/2019 -
A prospective, multicentre, randomised, controlled study evaluating SIR-Spheres® Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM)
Investigador/a principal: Jordi Bruix TudoCódigo: SIRCCADuración: 03/01/2016 -
Molecular regulation of the progression from hepatic steatosis to cirrhosis and hepatocellular carcinoma: Role and therapeutic potential of CPEB proteins.
Investigador/a principal: Jordi Bruix TudoCódigo: GCB15152955MENDDuración: 01/02/2015 - 31/12/2020 -
A Phase 1/2, Dose-escalation, Open-label Study of Nivolumab or Nivolumab in Combination with Other Agents in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis
Investigador/a principal: Jordi Bruix TudoCódigo: CA209040Duración: 01/02/2015